High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile

Biological Research

Volumn 40, Issue 3, 2007, Pages 365-372

  Guzmán, Leda M ^a,e   Koriyama, Chihaya ^b   Akiba, Suminori ^b   Eizuru, Yoshito ^b   Castillo, Darwins ^c   Corvalan, Alejandro ^c,d   Aguayo, Francisco R ^b,d  

^a UNIVERSIDAD SANTO TOMÁS   (Chile)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c INSTITUTO DE SALUD PÚBLICA DE CHILE   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE VALPARAÍSO   (Chile)

Author keywords

Lung carcinoma; Methylation; Promoter region

Indexed keywords

DNA; PROTEIN P16;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CELL CYCLE REGULATION; CHILE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE FREQUENCY; GENE INACTIVATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; SMOKING; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 41849107533     PISSN: 07169760     EISSN: 07176287     Source Type: Journal    
DOI: 10.4067/S0716-97602007000400011     Document Type: Article

References (38)

1. ADONIS M, GIL L (2000) Polycyclic aromatic hydrocarbon levels and mutagenicity of inhalable particulate matter in Santiago, Chile. Inhal Toxicol 12: 1173-83
2. ADONIS W, AGUAYO F, CORDERO E, RODRÍGUEZ L, CASTILLO D and GUZMÁN L (2006). Evaluación de hipermetilación del gen p16INK4 - en cáncer escamoso de pulmón en pacientes chilenos, Rev Ch Enf Resp, 22: 7-12
3. BELINSKY SA, NIKULA KJ, PALMISANO WA, MICHELS R, SACCOMANNO G, GABRIELSON E, BAYLIN SB, HERMAN JG (1998) Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 95: 11891-11896
4. BELINSKY SA, SNOW SS, NIKULA KJ, FINCH GL, TELLEZ CS, PALMISANO WA (2002) Aberrant CpG island methylation of the p16(INK4a) and estrogen receptor genes in rat lung tumours induced by particulate carcinogens. Carcinogenesis 23: 335-339
5. BELINSKY SA (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 707-717
6. BELINSKY SA, LIECHTY KC, GENTRY FD, WOLF HJ, ROGERS J, VU K, HANEY J, KENNEDY TC, HIRSCH FR, MILLER Y, FRANKLIN WA, HERMAN JG, BAYLIN SB, BUNN PA, BYERS T (2006) Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66: 3338-3344
7. BELINSKY SA, GRIMES MJ, CASAS E, STIDLEY CA, FRANKLIN WA, BOCKLAGE TJ, JOHNSON DH, SCHILLER JH (2007) Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 96: 1278-1283
8. CALLINAN PA, FEINBERG AP (2006) The emerging science of epigenomics. Hum Mol Genet 15 Spec No 1: R95-101
9. CASSIDY A, DUFFY SW, MYLES JP, LILOGLOU T, FIELD JK (2007) Lung cancer risk prediction: a tool for early detection. Int J Cancer 120: 1-6
10. COOMBS NJ, GOUGH AC, PRIMROSE JN (1999) Optimisation of DNA and RNA extraction from archival formalin-fixed tissue. Nucleic Acids Res 27: e12
11. DIGEL W, LUBBERT M (2005) DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit Rev Oncol Hematol 55: 1-11
12. ESTELLER M (2002) CpG island hypermethylation and tumour suppressor genes: a booming present, a brighter future. Oncogene 21: 5427-5440
13. ESTELLER M (2003) Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol 532: 39-49
14. FAN X, INDA MM, TUÑON T AND CASTRESANA JS (2002) Improvement of the methylation specific PCR technical conditions for the detection of p16 promoter hypermethylation in small amounts of tumour DNA. Oncol Rep 9: 181-183
15. GIL L, KING L, ADONIS M (2000) Trends of polycyclic aromatic hydrocarbon levels and mutagenicity in Santiago's inhalable airborne particles in the period 1992-1996.Inhal Toxicol 12: 1185-204
16. GREENLEE RT, HILL-HARMON MB, MURRAY T AND THUN M (2001) Cancer statistics, 2001. CA Cancer J Clin 51: 15-36. Erratum in: CA Cancer J Clin 2001;51: 144
17. HECHT SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91: 1194-1210
18. HERMAN JG, MERLO A, MAO L, LAPIDUS RG, ISSA JP, DAVIDSON NE, SIDRANSKY D, BAYLIN SB (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-30
19. HERMAN JG, GRAFF JR, MYÖHÄNEN S, NELKIN BD AND BAYLIN SB (1996) Methylation -specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93: 9821-9826
20. HERMAN JG, BAYLIN SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054
21. HILBE W, DIRNHOFER S, GREIL R, WOLL E (2004) Biomarkers in non-small cell lung cancer prevention. Eur J Cancer Prev 13: 425-436
22. LIU Y, LAN Q, SIEGFRIED JM, LUKETICH JD, KEOHAVONG P (2006) Aberrant promoter methylation of p16 and MGMT genes in lung tumours from smoking and never-smoking lung cancer patients. Neoplasia 8: 46-51
23. MERLO A, HERMAN JG, MAO L, LEE DJ, GABRIELSON E, BURGER PC, BAYLIN SB, SIDRANSKY D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692
24. MOMPARLER RL (2005) Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol 32: 443-451
25. NAKATA S, SUGIO K, URAMOTO H, OYAMA T, HANAGIRI T, MORITA M, YASUMOTO K (2006) The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 106: 2190-2199
26. NUOVO GJ, PLAIA TW, BELINSKY SA, BAYLIN SB, HERMAN JG (1999) In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 96: 12754-12759
27. PISANI P, BRAY F, PARKIN DM (2002) Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97: 72-81
28. PULLING LC, DIVINE KK, KLINGE DM, GILLILAND FD, KANG T, SCHWARTZ AG, BOCKLAGE TJ, BELINSKY SA (2003) Promoter hypermethylation of the 06-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumour progression. Cancer Res 63: 4842-4848
29. SANCHEZ-CESPEDES M, DECKER PA, DOFFEK KM, ESTELLER M, WESTRA WH, ALAWI EA, HERMAN JG, DEMEURE MJ, SIDRANSKY D, AHRENDT SA (2001) Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res 61: 2092-2096
30. SHIELDS PG (2002) Molecular epidemiology of smoking and lung cancer. Oncogene 21: 6870-6876
31. SZOT J (2003) Epidemiological analysis of mortality caused by solid tumours in the Metropolitan Region, Chile, 1999. Rev Med Chil 131: 641-9
32. TANAKA R, WANG D, MORISHITA Y, INADOME Y, MINAMI Y, IIJIMA T, FUKAI S, GOYA T, NOGUCHI M (2005) Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer 103: 608-615
33. TOYOOKA S, TSUDA T, GAZDAR AF (2003). The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2: 229-239
34. TRAVIS WD, BRAMBILLA E, MULLER-HERMELINK HK AND HARRIS CC (2004) Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart: World Health Organization. Classification of Tumours. Pathology & Genetics. Travis WD, Brambilla E, Muller-Hermelink Hk and Harris Cc (eds). International Agency for Research on Cancer (IARC): Lyon, pp. 9-124
35. WIKENHEISER-BROKAMP KA (2006) Retinoblastoma regulatory pathway in lung cancer. Curr Mol Med 6: 783-793
36. WISTUBA II, MAO L AND GAZDAR AF (2002) Smoking molecular damage in bronchial epithelium. Oncogene 21: 7298-7306
37. WISTUBA II (2007) Genetics of preneoplasia: lessons from lung cancer. Curr Mol Med 7: 3-14
38. ZOCHBAUER-MULLER S, FONG KM, VIRMANI AK, GERADTS J, GAZDAR AF, MINNA J (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255